AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
April 24, 2026 - … AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL … THOUSAND OAKS, Calif. , April 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its … AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL …
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
April 22, 2026 - … AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE … THOUSAND OAKS, Calif. , April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of …
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
April 6, 2026 - … AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR … LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR … 3 mm THOUSAND OAKS, Calif. , April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline results …
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
March 28, 2026 - … THOUSAND OAKS, Calif. , March 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Repatha ® … executive vice president of Research and Development at Amgen . "The new ACC/AHA Multisociety Guideline on the … intensify lipid-lowering therapy." For more information on Amgen abstracts and presentation times at the ACC 75th Annual …
AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
March 5, 2026 - … AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL … THOUSAND OAKS, Calif. , March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 … AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL …
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
March 4, 2026 - … AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND 03.04.2026 … THOUSAND OAKS, Calif. , March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of … AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND … AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND AMGEN ANNOUNCES …
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
February 24, 2026 - … AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE … THOUSAND OAKS, Calif. , Feb. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 46 th Annual TD Cowen … AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE …
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
February 13, 2026 - … AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP … THOUSAND OAKS, Calif. , Feb. 13, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual … AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP …
EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
February 12, 2026 - … EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS 02.12.2026 … THOUSAND OAKS, Calif., Feb. 12, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the European Commission …
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
February 3, 2026 - … AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL … THOUSAND OAKS, Calif. , Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for … AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL …